Transient Leukopenia Induced by Combination Therapy for Severe SARS-CoV-2 Pneumonia

Treatment strategies for patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to be heavily researched and ever-changing. Recent data has suggested that combination therapy with dexamethasone, remdesivir and baricitinib could decrease the severity and length of illness...

Full description

Saved in:
Bibliographic Details
Published in:European journal of case reports in internal medicine 2022-10, Vol.9 (10), p.003636-003636
Main Authors: Sullivan, Sierra, Leelaviwat, Natnicha, Davalos, Jesus, Evans, Abbie, Abdelnabi, Mahmoud, Mittal, Neha
Format: Article
Language:English
Subjects:
baricitinib
dexamethasone
remdesivir
sar-cov-2 pneumonia
transient leukopenia
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment strategies for patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to be heavily researched and ever-changing. Recent data has suggested that combination therapy with dexamethasone, remdesivir and baricitinib could decrease the severity and length of illness in patients with severe SARS-CoV-2. However; the data regarding the safety and side effects related to this combination therapy are limited to case reports. The purpose of this case report is to highlight a potentially life-threatening side effect of one or all medications mentioned above.
ISSN:2284-2594
2284-2594
DOI:10.12890/2022_003636